Combination Immunotherapy for Type 1 Diabetes

Robert N. Bone, Carmella Evans-Molina

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Purpose of Review: Type 1 diabetes (T1D) is an autoimmune disease marked by β-cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have focused on restoration of tolerance, T cell or B cell inhibition, regulatory T cell (Treg) induction, suppression of innate immunity and inflammation, immune system reset, and islet transplantation. The purpose of this review is to provide an overview and lessons learned from single immunotherapy trials, describe recent and ongoing combination immunotherapy trials, and provide perspectives on strategies for future combination clinical interventions aimed at preserving insulin secretion in T1D. Recent Findings: Combination immunotherapies have had mixed results in improving short-term glycemic control and insulin secretion in recent-onset T1D. Summary: A handful of studies have successfully reached their primary end-point of improved insulin secretion in recent-onset T1D. However, long-term improvements glycemic control and the restoration of insulin independence remain elusive. Future interventions should focus on strategies that combine immunomodulation with efforts to alleviate β-cell stress and address the formation of antigens that activate autoimmunity.

Original languageEnglish (US)
Article number50
JournalCurrent Diabetes Reports
Volume17
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Type 1 Diabetes Mellitus
Immunotherapy
Insulin
Islets of Langerhans Transplantation
Immunomodulation
Regulatory T-Lymphocytes
Autoimmunity
Innate Immunity
Autoimmune Diseases
Immune System
B-Lymphocytes
Inflammation
T-Lymphocytes
Antigens

Keywords

  • Clinical trials
  • Immune modulation
  • Neo-antigen
  • Tolerance restoration
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Combination Immunotherapy for Type 1 Diabetes. / Bone, Robert N.; Evans-Molina, Carmella.

In: Current Diabetes Reports, Vol. 17, No. 7, 50, 01.07.2017.

Research output: Contribution to journalReview article

@article{8b6dde538f2c4830a08f2a8a47d04362,
title = "Combination Immunotherapy for Type 1 Diabetes",
abstract = "Purpose of Review: Type 1 diabetes (T1D) is an autoimmune disease marked by β-cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have focused on restoration of tolerance, T cell or B cell inhibition, regulatory T cell (Treg) induction, suppression of innate immunity and inflammation, immune system reset, and islet transplantation. The purpose of this review is to provide an overview and lessons learned from single immunotherapy trials, describe recent and ongoing combination immunotherapy trials, and provide perspectives on strategies for future combination clinical interventions aimed at preserving insulin secretion in T1D. Recent Findings: Combination immunotherapies have had mixed results in improving short-term glycemic control and insulin secretion in recent-onset T1D. Summary: A handful of studies have successfully reached their primary end-point of improved insulin secretion in recent-onset T1D. However, long-term improvements glycemic control and the restoration of insulin independence remain elusive. Future interventions should focus on strategies that combine immunomodulation with efforts to alleviate β-cell stress and address the formation of antigens that activate autoimmunity.",
keywords = "Clinical trials, Immune modulation, Neo-antigen, Tolerance restoration, Type 1 diabetes",
author = "Bone, {Robert N.} and Carmella Evans-Molina",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s11892-017-0878-z",
language = "English (US)",
volume = "17",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "7",

}

TY - JOUR

T1 - Combination Immunotherapy for Type 1 Diabetes

AU - Bone, Robert N.

AU - Evans-Molina, Carmella

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose of Review: Type 1 diabetes (T1D) is an autoimmune disease marked by β-cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have focused on restoration of tolerance, T cell or B cell inhibition, regulatory T cell (Treg) induction, suppression of innate immunity and inflammation, immune system reset, and islet transplantation. The purpose of this review is to provide an overview and lessons learned from single immunotherapy trials, describe recent and ongoing combination immunotherapy trials, and provide perspectives on strategies for future combination clinical interventions aimed at preserving insulin secretion in T1D. Recent Findings: Combination immunotherapies have had mixed results in improving short-term glycemic control and insulin secretion in recent-onset T1D. Summary: A handful of studies have successfully reached their primary end-point of improved insulin secretion in recent-onset T1D. However, long-term improvements glycemic control and the restoration of insulin independence remain elusive. Future interventions should focus on strategies that combine immunomodulation with efforts to alleviate β-cell stress and address the formation of antigens that activate autoimmunity.

AB - Purpose of Review: Type 1 diabetes (T1D) is an autoimmune disease marked by β-cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have focused on restoration of tolerance, T cell or B cell inhibition, regulatory T cell (Treg) induction, suppression of innate immunity and inflammation, immune system reset, and islet transplantation. The purpose of this review is to provide an overview and lessons learned from single immunotherapy trials, describe recent and ongoing combination immunotherapy trials, and provide perspectives on strategies for future combination clinical interventions aimed at preserving insulin secretion in T1D. Recent Findings: Combination immunotherapies have had mixed results in improving short-term glycemic control and insulin secretion in recent-onset T1D. Summary: A handful of studies have successfully reached their primary end-point of improved insulin secretion in recent-onset T1D. However, long-term improvements glycemic control and the restoration of insulin independence remain elusive. Future interventions should focus on strategies that combine immunomodulation with efforts to alleviate β-cell stress and address the formation of antigens that activate autoimmunity.

KW - Clinical trials

KW - Immune modulation

KW - Neo-antigen

KW - Tolerance restoration

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85019954010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019954010&partnerID=8YFLogxK

U2 - 10.1007/s11892-017-0878-z

DO - 10.1007/s11892-017-0878-z

M3 - Review article

VL - 17

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 7

M1 - 50

ER -